| Recruiting | 2 | 136 | RoW | CX-4945 (SARS-CoV-2 domain), Silmitasertib, Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain), Placebo (Influenza virus domain) | Senhwa Biosciences, Inc. | Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia | 03/25 | 06/25 | | |
NCT05097053: A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 |
|
|
| Recruiting | 4 | 200 | RoW | MVC-COV1901(3 Months), MVC-COV1901(6 Months) | Taoyuan General Hospital, Medigen Vaccine Biologics Corp. | COVID-19 Vaccine | 03/22 | 07/22 | | |